Technology Brief: Genetic Signature for the Identification of Metastatic Melanoma

Docket Number: 06B073

Summary	• Gene expression analyzed in 250 primary and metastatic melanomas procured at the time of surgical resection • Approximately 1,000 genes identified to be differentially expressed in the transition from primary to metastatic melanoma • A subset of 60 genes for which differential expression is associated with metastatic potential and tumor thickness
Features and Benefits	• Can aid in the pathology determination of tumor when histology or morphology are inconclusive • Distinguish between new primary tumors or metastasized tumors from a different primary source • Adaptable to gene chip or related diagnostic devices
Stage of Development	The gene expression signature continues to be developed in an effort to minimize the number of genes needed for a diagnostic test for melanoma metastatic condition.
Inventor	Dr. A. Riker and Dr. S.A. Enkemann
Publication and Patent Status	A. Riker et al. (2008) BMC Med. Genomics 1:13. Utility patent application granted.

Contact: Ray Carpenter
Sr. Intellectual Property Associate
Office of Technology Management and Licensing
H. Lee Moffitt Cancer Center and Research Institute
12902 Magnolia Drive MRC-TTO
Tampa, FL 33612
Email: Ray.Carpenter@moffitt.org
Telephone: 813-745-6902
Website: http://www.moffitt.org/OTMC